Target intelligence / Profile preview

Urinary tract mucosal sensory nerve endings

Molecular classification
Nerve ending, Ion channel, G protein-coupled receptor, Neuropeptide receptor
01

Overview

Urinary tract mucosal sensory nerve endings are specialized afferent fibers, primarily A-delta and C-fibers, located within the urothelium and suburothelial space of the bladder and urethra (Fowler et al., 2008). These nerve endings serve as the primary sensors for mechanical stretch and chemical stimuli, transmitting signals to the central nervous system to regulate the micturition reflex and signal pain (Birder & Andersson, 2013). They express a diverse array of molecular targets, including Transient Receptor Potential Vanilloid 1 (TRPV1), purinergic P2X3 receptors, and acid-sensing ion channels (ASICs) (Andersson, 2002). In conditions like overactive bladder (OAB) and interstitial cystitis, these sensory endings exhibit hypersensitivity or increased density, contributing to symptoms of urgency and chronic pelvic pain (Wyndaele et al., 2001). Therapeutic strategies often target these endings through intravesical administration of drugs like lidocaine to block sodium channels or capsaicin to desensitize TRPV1 receptors (Chancellor & de Groat, 1999). Additionally, botulinum toxin A is utilized to inhibit the release of sensory neuropeptides such as Substance P and Calcitonin Gene-Related Peptide (CGRP) from these terminals (Apostolidis et al., 2006).

Other names
Bladder mucosal afferentsSuburothelial sensory nervesUrinary tract afferent nerve endingsUrothelial sensory fibers
02

Mechanism of action

Inhibition of voltage-gated sodium channels, desensitization of TRPV1 ion channels, and blockade of SNAP-25 mediated exocytosis of sensory neuropeptides (Fowler et al., 2008; Apostolidis et al., 2006).

03

Biological functions

MechanosensationChemosensationNociceptionRegulation of the micturition reflexRelease of inflammatory neuropeptides
04

Disease associations

Overactive bladderInterstitial cystitisBladder pain syndromeNeurogenic detrusor overactivityChronic pelvic pain syndrome
05

Safety considerations

Urinary retentionImpaired bladder emptyingLoss of protective sensationLocal injection site painSystemic toxicity from local anesthetic absorption
06

Interacting drugs

Lidocaine

5 more in the full profile.

07

Biomarkers

Urinary Nerve Growth Factor (NGF)Urinary Calcitonin Gene-Related Peptide (CGRP)Substance P levels in bladder tissue

Beyond the preview

Go deeper on Urinary tract mucosal sensory nerve endings.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Urinary tract mucosal sensory nerve endings.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call